tirzepatide and semaglutide injections vs Troubling Findings in Study of

On April 24, 2025, a federal court ruling confirmed that the FDAs prior enforcement discretion for compounded semaglutide has ended for state-licensed pharmacies and physicians (503A)

South America Glutathione Market Size and Forecast, by Country (2025-2032) 9.4.1

There are benefits and downsides to switching from Wegovy injections to Wegovy tablets

This massive multicenter study included 810,390 new semaglutide users and found NAION incidence rates of 14.5 per 100,000 person-years among semaglutide patients, with increased risks particularly evident at the 2-year, 3-year, and 4-year timepoints following treatment initiation